ARTICLE | Clinical News

NCX 6560: Additional Phase Ib data

December 13, 2010 8:00 AM UTC

Data from 48 healthy male volunteers with high LDL-C in the second part of a 3-part, double-blind Phase Ib trial showed that 24, 48, 96 or 144 mg NCX 6560 led to dose-dependent reductions from baseline of up to 57% in LDL-C, 45% in total cholesterol and 49% in apolipoprotein B (APOB) at day 14. Furthermore, 48 mg NCX 6560 displayed the same lipid-lowering effects as 40 mg Lipitor atorvastatin. NCX 6560 was well tolerated with no serious adverse events or significant increases in liver enzymes observed. Data were presented at the American Heart Association meeting in Chicago. ...